Trial Profile
Phase I investigator initiated clinical trial using a novel WT1 peptide vaccine for patients with metastatic pancreatic cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 10 Apr 2018
Price :
$35
*
At a glance
- Drugs Adegramotide/nelatimotide (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer; Squamous cell cancer
- Focus Adverse reactions
- 07 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 11 Oct 2017 New trial record